ADMISSION OF SHARES TO AIM

27 April 2012

LSE: VER

Vernalis plc

Admission of Shares to AIM

With effect from 8:00 a.m. today, Vernalis' ordinary shares of 1 pence each ("Ordinary Shares") will be admitted to trading on AIM and the Company's listing on the premium segment of the Official List and trading on the London Stock Exchange's main market for listed securities will both be cancelled.

At admission to AIM, there will be 442,112,768 Ordinary Shares in issue. The ISIN and ticker for the Company's shares will continue to be GB00B3Y5L754 and VER respectively.

Nomura Code Securities Limited will act as the Company's Nominated Adviser (Nomad) pursuant to the AIM rules.

Enquiries:

Notes to Editors

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough/cold market as well as eight programmes in its NCE development pipeline. Vernalis has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, GSK, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com

Vernalis Forward-Looking Statement

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.